for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regenxbio Inc

RGNX.O

Latest Trade

30.30USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

27.02

 - 

50.26

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

REGENXBIO Announces Orphan Drug Designation For Duchenne Muscular Dystrophy Gene Therapy

Nov 22 (Reuters) - Regenxbio Inc <RGNX.O>::REGENXBIO ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO RGX-202, A NOVEL GENE THERAPY CANDIDATE FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.REGENXBIO INC - COMPANY ON TRACK TO SUBMIT IND BY END OF 2021.REGENXBIO INC - INTERNAL CGMP FACILITY IS EXPECTED TO ALLOW FOR PRODUCTION UP TO 2,000 LITERS FOR CLINICAL DEVELOPMENT OF RGX-202.

Abeona Therapeutics On Nov 12 Entered Into Settlement Agreement With Regenxbio - Filing

Nov 15 (Reuters) - Abeona Therapeutics Inc <ABEO.O>::ABEONA THERAPEUTICS - ON NOV 12, ENTERED INTO SETTLEMENT AGREEMENT WITH REGENXBIO - FILING.ABEONA THERAPEUTICS-SETTLEMENT AGREEMENT WITH REGENXBIO TO RESOLVE ARBITRATIONS, RELATED PROCEEDINGS ARISING FROM LICENSE AGREEMENT DATED NOV 4, 2018.ABEONA THERAPEUTICS - PURSUANT TO TERMS OF SETTLEMENT AGREEMENT, CO WILL PAY TO REGENXBIO A TOTAL OF $30 MILLION.

Regenxbio Presents Additional Positive Interim Data From Trials Of Rgx-314 In Wet AMD And Diabetic Retinopathy Using Suprachoroidal Delivery At Aao 2021

Nov 12 (Reuters) - Regenxbio Inc <RGNX.O>::REGENXBIO PRESENTS ADDITIONAL POSITIVE INTERIM DATA FROM TRIALS OF RGX-314 IN WET AMD AND DIABETIC RETINOPATHY USING SUPRACHOROIDAL DELIVERY AT AAO 2021.REGENXBIO INC - SUPRACHOROIDAL DELIVERY OF RGX-314 IN PHASE II AAVIATE® TRIAL FOR TREATMENT OF WET AMD CONTINUES TO BE WELL TOLERATED.REGENXBIO INC - POSITIVE INITIAL DATA FROM COHORT 2 IN AAVIATE TRIAL AT SIX MONTHS AFTER ONE-TIME TREATMENT OF RGX-314.REGENXBIO INC - TREATMENT EFFECT OBSERVED WITH STABLE VISUAL ACUITY AND RETINAL THICKNESS.REGENXBIO INC - DEMONSTRATED MEANINGFUL REDUCTION (>70%) IN ANTI-VEGF TREATMENT BURDEN; 40% OF PATIENTS IN COHORT 2 WERE ANTI-VEGF INJECTION-FREE.

Regenxbio Posts Quarterly Loss Per Share Of $1.37

Nov 2 (Reuters) - Regenxbio Inc <RGNX.O>::REGENXBIO REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.$533.5 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPTEMBER 30, 2021.ON TRACK TO FILE IND FOR RGX-202 FOR TREATMENT OF DUCHENNE BY END OF 2021.REVENUES WERE $30.8 MILLION FOR THREE MONTHS ENDED SEPTEMBER 30, 2021, COMPARED TO $98.9 MILLION FOR THREE MONTHS ENDED SEPTEMBER 30, 2020.QTRLY LOSS PER SHARE $1.37.EXPECTS ITS BALANCE IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TO FUND ITS OPERATIONS INTO SECOND HALF OF 2023.Q3 EARNINGS PER SHARE VIEW $-1.08, REVENUE VIEW $41.5 MILLION -- REFINITIV IBES DATA.

Abbvie And Regenxbio Announce Eye Care Collaboration

Sept 13 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE AND REGENXBIO ANNOUNCE EYE CARE COLLABORATION.ABBVIE INC - ABBVIE WILL PAY REGENXBIO A $370 MILLION UPFRONT PAYMENT.ABBVIE INC - DEAL INCLUDES POTENTIAL FOR REGENXBIO TO RECEIVE UP TO $1.38 BILLION IN ADDITIONAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES.ABBVIE INC - DEAL FOR REGENXBIO AND ABBVIE WILL SHARE EQUALLY IN PROFITS FROM NET SALES OF RGX-314 IN U.S..ABBVIE INC - DEAL FOR ABBVIE WILL PAY REGENXBIO TIERED ROYALTIES ON NET SALES OF RGX-314 OUTSIDE U.S..ABBVIE INC - ABBVIE WILL PAY REGENXBIO TIERED ROYALTIES ON NET SALES OF RGX-314 OUTSIDE U.S..ABBVIE INC - REGENXBIO WILL LEAD MANUFACTURING OF RGX-314 FOR CLINICAL DEVELOPMENT AND U.S. COMMERCIAL SUPPLY.ABBVIE INC - ABBVIE WILL LEAD MANUFACTURING OF RGX-314 FOR COMMERCIAL SUPPLY OUTSIDE U.S..ABBVIE INC - REGENXBIO WILL BE RESPONSIBLE FOR COMPLETION OF ONGOING TRIALS OF RGX-314.ABBVIE INC - ABBVIE WILL LEAD CLINICAL DEVELOPMENT AND COMMERCIALIZATION OF RGX-314 GLOBALLY.ABBVIE INC - ABBVIE AND REGENXBIO WILL COLLABORATE AND SHARE COSTS ON ADDITIONAL TRIALS OF RGX-314.

Regenxbio Reports Second Quarter 2021 Financial Results And Operational Highlights

Aug 9 (Reuters) - Regenxbio Inc <RGNX.O>::REGENXBIO REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q2 LOSS PER SHARE $1.36.Q2 EARNINGS PER SHARE ESTIMATE $-1.12 -- REFINITIV IBES DATA.EXPECTS TO FILE IND FOR RGX-202 FOR TREATMENT OF DUCHENNE BY END OF 2021.$593 MILLION IN CASH, EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2021.REGENXBIO - SEES BALANCE IN CASH, EQUIVALENTS AS OF JUNE 30, 2021, TO FUND OPERATIONS INTO H2 2023.QTRLY LOSS PER SHARE $1.36.QTRLY REVENUES $22.0 MILLION VERSUS $16.6 MILLION.Q2 EARNINGS PER SHARE VIEW $-1.12, REVENUE VIEW $29.0 MILLION -- REFINITIV IBES DATA.

Abeona Intends To Seek Enforcement Of Settlement Agreement

July 16 (Reuters) - Abeona Therapeutics Inc <ABEO.O>::ABEONA - ON JULY 13,TRIBUNAL OF AMERICAN ARBITRATION ASSOCIATION FOUND IN FAVOR OF REGENXBIO IN CONNECTION WITH PARTIES' ARBITRATION CLAIMS, COUNTERCLAIMS.ABEONA - TRIBUNAL AWARDED REGENXBIO $28 MILLION PLUS INTEREST IN CONNECTION WITH COMPANIES' FORMER LICENSE AGREEMENT ENTERED INTO IN NOVEMBER 2018.ABEONA THERAPEUTICS INC - ABEONA INTENDS TO SEEK ENFORCEMENT OF SETTLEMENT AGREEMENT.

Regenxbio Inc - On July 13, Arbitration Tribunal Awarded Co $28.0 Million In Damages, Plus About $6.1 Million In Accrued Interest

July 16 (Reuters) - Abeona Therapeutics Inc <ABEO.O>::REGENXBIO INC - ON JULY 13, ARBITRATION TRIBUNAL AWARDED CO $28.0 MILLION IN DAMAGES, PLUS ABOUT $6.1 MILLION IN ACCRUED INTEREST.REGENXBIO INC - ANTICIPATES TAKING APPROPRIATE MEASURES TO ENFORCE AWARD IF ABEONA DOES NOT COMPLY WITH TRIBUNAL'S RULING.REGENXBIO INC - CANNOT BE CERTAIN OF PRECISE TIMING OR AMOUNT OF RECOVERY.

Regenxbio Presents Additional Positive Interim Data From Phase I/II Trial Of RGX-121

May 14 (Reuters) - Regenxbio Inc <RGNX.O>::REGENXBIO PRESENTS ADDITIONAL POSITIVE INTERIM DATA FROM PHASE I/II TRIAL OF RGX-121 FOR THE TREATMENT OF MPS II (HUNTER SYNDROME) AT AMERICAN SOCIETY OF GENE AND CELL THERAPY'S 24TH ANNUAL MEETING.REGENXBIO - RGX-121 CONTINUES TO BE WELL-TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS.REGENXBIO - BIOMARKERS AND MEASURES OF NEURODEVELOPMENTAL FUNCTION CONTINUE TO INDICATE CNS ACTIVITY FOLLOWING RGX-121 ADMINISTRATION.REGENXBIO INC - EVIDENCE OF SYSTEMIC ENZYME EXPRESSION AND BIOMARKER ACTIVITY CONTINUES TO BE OBSERVED.

Regenxbio Reports Q1 Loss Per Share Of $1.20

May 5 (Reuters) - Regenxbio Inc <RGNX.O>::REGENXBIO REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q1 LOSS PER SHARE $1.20.IND FILING EXPECTED IN MID-2021 FOR RGX-202.$657 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2021.EXPECTS CURRENT BALANCE IN CASH, EQUIVALENTS TO FUND ITS OPERATIONS INTO SECOND HALF OF 2023.Q1 EARNINGS PER SHARE VIEW $-1.28 -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up